Efficacy and tolerability of two oral hyoscine butylbromide formulations in Chinese patients with recurrent episodes of self-reported gastric or intestinal spasm-like pain

被引:9
作者
Ge, Z. [3 ]
Yuan, Y. [4 ]
Zhang, S. [5 ]
Hou, X. [6 ]
Wang, J. [7 ]
Cai, J. [8 ]
Shi, R. [9 ]
Li, Y. [10 ]
Wang, B. [11 ]
Ji, F. [2 ]
Richter, E. [1 ]
Schaefer, E. [1 ]
机构
[1] Boehringer Ingelheim KG, D-6507 Ingelheim, Germany
[2] Zhejiang Univ, Sch Med, Affiliated Hosp 1, Hangzhou 310003, Zhejiang, Peoples R China
[3] Shanghai Jiao Tong Univ, Sch Med, Renji Hosp, Shanghai 200030, Peoples R China
[4] Shanghai Jiao Tong Univ, Sch Med, Ruijin Hosp, Shanghai 200030, Peoples R China
[5] Capital Med Univ, Beijing Friendship Hosp, Beijing, Peoples R China
[6] Huazhong Univ Sci & Technol, Union Hosp, Tongji Med Coll, Wuhan 430074, Peoples R China
[7] Fudan Univ, Shanghai Med Coll, Zhongshan Hosp, Shanghai 200433, Peoples R China
[8] Zhejiang Univ, Sch Med, Affiliated Hosp 2, Hangzhou 310003, Zhejiang, Peoples R China
[9] Nanjing Med Univ, Affiliated Hosp 1, Nanjing, Peoples R China
[10] Shandong Univ, Qilu Hosp, Jinan 250100, Peoples R China
[11] Tianjin Med Univ Gen Hosp, Tianjin, Peoples R China
关键词
abdominal pain; abdominal cramps; functional colonic diseases; antispasmodic agents; hyoscine butylbromide; IRRITABLE-BOWEL-SYNDROME; PREVALENCE;
D O I
10.5414/CP201485
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Aim: To compare the efficacy and tolerability of oral hyoscine butylbromide tablets and capsules in Chinese patients with recurrent episodes of self-reported gastric or intestinal spasm-like pain and to show non-inferiority of both formulations. Methods: 302 patients were entered into a randomized, double-blind, double-dummy, active-controlled 2-arm parallel group study. They were randomized to 3 days of treatment with hyoscine butylbromide tablets or capsules. In patient diaries the pain intensity was assessed on 10 cm visual analogue scales on Day 1 (0, 30, 60, 90, 120, and 180 minutes after first dose), Days 2, and 3 (maximum pain intensity once daily). Pain frequency, overall efficacy, and tolerability were assessed on verbal rating scales. Results: In the per-protocol dataset 281 patients were analyzed. The change from baseline after 180 minutes was 59% in both treatment groups; the adjusted means of pain intensity on Day 1 were reduced by 2.36 cm (tablets) and -2.31 cm (capsules). Pain intensity decreased within 30 minutes by approximately 20%. The decrease of the peak pain intensity was approximately 55% after 3 days in both treatment groups; the adjusted means after 3 days were reduced by -2.48 cm (tablets) and by -2.45 cm (capsules). Abdominal pain frequency decreased by 50% (tablets) and 42% (capsules). Both treatments were well tolerated. Drug-related adverse events were infrequent (3.5%). No serious adverse event occurred. Conclusions: Hyoscine butylbromide is effective in the treatment of recurrent gastric or intestinal spasm-like pain and well tolerated. Non-inferiority of tablets and capsules was demonstrated.
引用
收藏
页码:198 / 205
页数:8
相关论文
共 22 条
[1]   Prevalence of irritable bowel syndrome (IBS) and variability of diagnostic criteria [J].
Bommelaer, G ;
Poynard, T ;
Le Pen, C ;
Gaudin, AF ;
Maurel, F ;
Priol, G ;
Amouretti, M ;
Frexinos, J ;
Ruszniewski, P ;
El Hasnaoui, A .
GASTROENTEROLOGIE CLINIQUE ET BIOLOGIQUE, 2004, 28 (6-7) :554-561
[2]  
Drossman DA., 1994, The Functional Gastrointestinal Disorders: Diagnosis, Pathophysiology and Treatment
[3]   Quaternary ammonium derivatives as Spasmolytics for irritable bowel syndrome [J].
Evangelista, S .
CURRENT PHARMACEUTICAL DESIGN, 2004, 10 (28) :3561-3568
[4]   Effect of fibre, antispasmodics, and peppermint oil in the treatment of irritable bowel syndrome: systematic review and meta-analysis (vol 337, a2313, 2008) [J].
Ford, Alexander C. .
BRITISH MEDICAL JOURNAL, 2009, 338
[5]   Effect of fibre, antispasmodics, and peppermint oil in the treatment of irritable bowel syndrome: systematic review and meta-analysis [J].
Ford, Alexander C. ;
Talley, Nicholas J. ;
Spiegel, Brennan M. R. ;
Foxx-Orenstein, Amy E. ;
Schiller, Lawrence ;
Quigley, Eamonn M. M. ;
Moayyedi, Paul .
BMJ-BRITISH MEDICAL JOURNAL, 2008, 337 :1388-1392
[6]  
HU PJ, 2003, CHIN J DIG DIS, V4, P147
[7]   The prevalence, patterns and impact of irritable bowel syndrome: an international survey of 40 000 subjects [J].
Hungin, APS ;
Whorwell, PJ ;
Tack, J ;
Mearin, F .
ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2003, 17 (05) :643-650
[8]   Pharmacologic treatment of the irritable bowel syndrome: A systematic review of randomized, controlled trials [J].
Jailwala, J ;
Imperiale, TF ;
Kroenke, K .
ANNALS OF INTERNAL MEDICINE, 2000, 133 (02) :136-147
[9]   TOWARDS POSITIVE DIAGNOSIS OF IRRITABLE BOWEL [J].
MANNING, AP ;
THOMPSON, WG ;
HEATON, KW ;
MORRIS, AF .
BRITISH MEDICAL JOURNAL, 1978, 2 (6138) :653-654
[10]   Drug therapy: Irritable bowel syndrome [J].
Mertz, HR .
NEW ENGLAND JOURNAL OF MEDICINE, 2003, 349 (22) :2136-2146